Related references
Note: Only part of the references are listed.Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study
Walter Ageno et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies
Andrew W. Swartz et al.
ONCOLOGIST (2021)
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Gary H. Lyman et al.
BLOOD ADVANCES (2021)
Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial
Robert D. McBane et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Robert D. McBane et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)
Andrea Marshall et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
Frits Mulder et al.
BLOOD (2020)
Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis
Michela Giustozzi et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis
Gary H. Lyman et al.
THROMBOSIS RESEARCH (2020)
Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism
Trine-Lise Hannevik et al.
THROMBOSIS RESEARCH (2020)
Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases
Avi Leader et al.
BLOOD ADVANCES (2020)
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Dominique Farge et al.
LANCET ONCOLOGY (2019)
Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors
B. J. Carney et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study
Noemie Kraaijpoel et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
J. I. Weitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer A population-based cohort study
Alexander T. Cohen et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study
Luis Jara-Palomares et al.
THROMBOSIS RESEARCH (2017)
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
S. Kaatz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12months: the DALTECAN Study
C. W. Francis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort
Hilde Jensvoll et al.
CLINICAL EPIDEMIOLOGY (2015)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
JW Blom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Share Paper
